These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20635923)

  • 21. Cancer vaccines: between the idea and the reality.
    Finn OJ
    Nat Rev Immunol; 2003 Aug; 3(8):630-41. PubMed ID: 12974478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer vaccines: preclinical studies and novel strategies.
    Palena C; Abrams SI; Schlom J; Hodge JW
    Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The revival of cancer vaccines - The eminent need to activate humoral immunity.
    Huijbers EJM; Griffioen AW
    Hum Vaccin Immunother; 2017 May; 13(5):1112-1114. PubMed ID: 28118089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peptide vaccines for cancer therapy.
    Cerezo D; Peña MJ; Mijares M; Martínez G; Blanca I; De Sanctis JB
    Recent Pat Inflamm Allergy Drug Discov; 2015; 9(1):38-45. PubMed ID: 25642777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA vaccines: successes and limitations in cancer and infectious disease.
    Lowe DB; Shearer MH; Kennedy RC
    J Cell Biochem; 2006 May; 98(2):235-42. PubMed ID: 16440328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Targets in Cancer Therapy - Fourth Biennial Meeting. Mechanism and therapeutic reversal of immune suppression in cancer.
    Herber DL
    IDrugs; 2007 Apr; 10(4):227-9. PubMed ID: 17390239
    [No Abstract]   [Full Text] [Related]  

  • 27. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines.
    Schijns V; Tartour E; Michalek J; Stathopoulos A; Dobrovolskienė NT; Strioga MM
    Cytotherapy; 2014 Apr; 16(4):427-39. PubMed ID: 24280238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer vaccines.
    Butterfield LH
    BMJ; 2015 Apr; 350():h988. PubMed ID: 25904595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL-13 receptor-directed cancer vaccines and immunotherapy.
    Nakashima H; Husain SR; Puri RK
    Immunotherapy; 2012 Apr; 4(4):443-51. PubMed ID: 22512637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Editorial: Approaches to Advance Cancer Vaccines to Clinical Utility.
    Van Nuffel AMT; Boudousquié C; Tuyaerts S
    Front Immunol; 2019; 10():2032. PubMed ID: 31507617
    [No Abstract]   [Full Text] [Related]  

  • 31. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
    Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
    Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Report on the sixth annual meeting of the Association for Immunotherapy of Cancer (CIMT), May 15 and 16, 2008 in Mainz, Germany.
    Welters MJ; van Montfoort N; Khan S; Meyer RG; Britten CM
    Cancer Immunol Immunother; 2009 May; 58(5):777-87. PubMed ID: 18982325
    [No Abstract]   [Full Text] [Related]  

  • 33. Translational development of vaccination strategies in follicular NHL.
    Sakamaki I; Qin H; Kwak LW
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.
    Bol KF; Schreibelt G; Gerritsen WR; de Vries IJ; Figdor CG
    Clin Cancer Res; 2016 Apr; 22(8):1897-906. PubMed ID: 27084743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy of surgical malignancies.
    Morse MA; Lyerly HK; Clay TM; Abdel-Wahab O; Chui SY; Garst J; Gollob J; Grossi PM; Kalady M; Mosca PJ; Onaitis M; Sampson JH; Seigler HF; Toloza EM; Tyler D; Vieweg J; Yang Y
    Curr Probl Surg; 2004 Jan; 41(1):15-132. PubMed ID: 14749625
    [No Abstract]   [Full Text] [Related]  

  • 36. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
    Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
    Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies for successful vaccination against hepatocellular carcinoma.
    Rinaldi M; Iurescia S; Fioretti D; Ponzetto A; Carloni G
    Int J Immunopathol Pharmacol; 2009; 22(2):269-77. PubMed ID: 19505380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antigen-specific vaccines for cancer treatment.
    Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Promises and limitations of murine models in the development of anticancer T-cell vaccines.
    Lévy F; Colombetti S
    Int Rev Immunol; 2006; 25(5-6):269-95. PubMed ID: 17169777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vaccine strategies against melanoma].
    Ghiringhelli F; Zitvogel L
    Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.